Here are five points:
1. The Phase I/Phase II grant totals $3.2 million.
2. BA-1049 is intended to treat cerebral cavernous malformations.
3. The terms of the grant allow BioAxone to partner with University of Chicago, Durham, N.C.-based Duke University and the Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center.
4. CCM mutation results in benign endothelial cell tumors, causing headaches, seizures and neurological complications.
5. The researchers will complete proof of concept studies to test the effectiveness of BA-1049 with human vascular tissue and transgenic mice expressing defective copies of the CCM gene.
“We are delighted that this grant has allowed us to form a strong consortium of industry and academic partners to develop the first effective drug to treat this disorder,” said Lisa McKerracher, PhD, CEO, BioAxone.
More articles on spine:
6 key notes on spinal fusion complications & length of stay
Drs. Ralph G. Dacey Jr., Dawn Tartaglione & more: 13 spine surgeons recently receiving honors — Feb. 8, 2016
Society of Neurological Surgeons names Dr. Ralph Dacey president: 4 key notes
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
